Everything below concerns 合成肽. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual inspection |
| Solubility | Soluble in aqueous buffer | Lipophilic chain lowers pure-water solubility |
| Long-term storage | -20 degrees Celsius or lower | With desiccant, protected from light |
| Short-term storage | 2 to 8 degrees Celsius | For dissolved aliquots |
| Typical purity method | Reversed-phase HPLC | Ultraviolet detection, often with mass confirmation |
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
) of the interaction between two or more molecules in solution. This is achieved by measuring the enthalpies of a series of binding reactions caused by injections of a solution of one molecule to a reaction cell containing a solution of another molecule. The enthalpy values are plotted over the molar ratios resulting from the injections. From the plot, the molar reaction enthalpy
=== Primary cold agglutinin disease === The primary form is caused by excessive cell proliferation of B lymphocytes, characterized by clonal lymphoproliferative disorder. Primary cold agglutinin disease occurs after the fifth decade of life and peaks prevalence in a person's 70s and 80s.
=== Cerebrospinal fluid === Cerebrospinal fluid (CSF) allows for regulation of the distribution of substances between cells of the brain, and neuroendocrine factors, to which slight changes can cause problems or damage to the nervous system. For example, high glycine concentration disrupts temperature and blood pressure control, and high CSF pH causes dizziness and syncope.
=== Coffee makers and single-use capsules === In September 2012, Starbucks announced plans to introduce the Verismo, a consumer-grade single-serve coffee machine that uses sealed plastic cups of coffee grounds, and a "milk pod" for lattes. In November 2012, Starbucks Verismo became publicly available, consisting of a line of coffee makers that brew espresso and regular chocolate from coffee capsules, a type of pre-apportioned single-use container of ground coffee and flavourings utilizing the K-Fee pod system.
Sources: en.wikipedia.org
== Interleukin antagonists == Interleukins are a cytokine that play a major role in the immune system. IL-12 and IL-23 help with the activation and differentiation of natural killer cells and CD4+ T lymphocyte, both of which contribute to inflammation. Interleukin antagonists, the most recent class of biologics available for use in IBD, inhibit the action of IL-12 and IL-23 by binding to the p40 protein subunit that is found on both of these cytokines.
Macroglossia Periorbital bruising Thromboembolisms Symmetric sensory neuropathy (such as bilateral carpal tunnel) Postural hypotension (secondary to autonomic neuropathy) Nephrotic syndrome (secondary to free light chain damage to the kidneys/deposition of amyloid in the kidneys)
=== Role of norepinephrine transporter (NET) === Approximately 90% of released NE from the sympathetic nerve fibers is taken up again by postganglionic adrenergic neurons through the protein NET. The reuptake of NE is either repackaged into vesicles or degraded by the enzyme monoamine oxidase (MAO). The NET is located in the plasma membrane of noradrenergic neurons and serves as the fundamental mechanism by terminating the biological effects of NE in the synapse. The NE inactivation process, when taken up by the NET, is crucial in preventing too much increase in the NE concentration in the synaptic cleft. The reuptake of NE is competitive with various naturally occurring amines and drugs.
== History == The orexin neuropeptides were discovered in 1998 and the role of the orexin system in the etiology of narcolepsy was identified between 1999 and 2000. Subsequent research further established the role of the orexin system in sleep–wake regulation. Due to the promising potential of orexin system modulation in the treatment of sleep disorders, these findings led to translational efforts to bring orexin receptor modulators to medicine as therapeutic agents. Suvorexant was developed by Merck. It entered clinical development in 2006 and was first described in the medical literature in 2010. The medication was approved by the FDA for the treatment of insomnia in the United States on 13 August 2014. Suvorexant was initially released November 2014 in Japan, then later reached the United States in February 2015, Australia in November 2016, and Canada in November 2018. It was the first orexin receptor antagonist to be introduced for medical use, and was followed by lemborexant in 2019 and daridorexant in 2022. Development of almorexant (ACT-078573) and filorexant (MK-6096) was discontinued, while seltorexant (MIN-202, JNJ-42847922) and vornorexant (ORN-0829, TS-142) are still in clinical trials. Suvorexant marketing exclusivity in the United States was set to expire in January 2023 and patent protection is set to expire in 2029 to 2033.
The remaining energy to initiate fission can be supplied by two other mechanisms: one of these is more kinetic energy of the incoming neutron, which is increasingly able to fission a fissionable heavy nucleus as it exceeds a kinetic energy of 1 MeV or more (so-called fast neutrons). Such high energy neutrons are able to fission 238U directly (see thermonuclear weapon for application, where the fast neutrons are supplied by nuclear fusion). However, this process cannot happen to a great extent in a nuclear reactor, as too small a fraction of the fission neutrons produced by any type of fission have enough energy to efficiently fission 238U. (For example, neutrons from thermal fission of 235U have a mean energy of 2 MeV, a median energy of 1.6 MeV, and a mode of 0.75 MeV, and the energy spectrum for fast fission is similar.) Among the heavy actinide elements, however, those isotopes that have an odd number of neutrons (such as 235U with 143 neutrons) bind an extra neutron with an additional 1 to 2 MeV of energy over an isotope of the same element with an even number of neutrons (such as 238U with 146 neutrons). This extra binding energy is made available as a result of the mechanism of neutron pairing effects, which itself is caused by the Pauli exclusion principle, allowing an extra neutron to occupy the same nuclear orbital as the last neutron in the nucleus.
Sources: en.wikipedia.org
It separates molecules by hydrophobicity, which is effective for distinguishing an intact peptide from truncated or chemically modified forms. A C18 column with an acidic water-organic mobile phase is a standard configuration.
Lyophilised powder is generally held at minus twenty degrees Celsius or lower for long-term storage. Once dissolved, aliquots are kept at two to eight degrees Celsius for short periods and should not be repeatedly frozen and thawed.
Photo-oxidation can modify tryptophan, methionine, and tyrosine residues, altering the structure. Amber glass containers or foil wrapping are routine measures to reduce light exposure.
It is normally kept frozen, desiccated, and away from light, with brief warming to room temperature before opening to limit condensation. Repeated freeze-thaw cycles are avoided because they stress the peptide. Once in solution, the material is held cold and used promptly.